Rare Diseases

The 2021 AAN Meeting Hot Topics plenary focused on neurological facets of COVID-19, and featured insight from Anthony Fauci, MD, of NIAID, and Walter Koroshetz, MD, of NINDS, among others.

A recent analysis of UnitedHealthcare insurance claims revealed increases of almost 200% for some services between 2001 and 2016.

PTC Therapeutics announced the initiation of its third study of 2020 investigating vatiquinone.

These data follow a recent announcement from Sio Gene Therapies that the first patient in the high-dose cohort has been dosed.

The chief medical officer at Cure SMA spoke to the ongoing work that the organization does in advocating for patients with spinal muscular atrophy, particularly for newborn screening.

This additional application, supported by data from the GWPCARE6 trial, seeks to expand the indication of cannabidiol to include seizures associated with tuberous sclerosis complex.

Study data demonstrates that treatment with satralizumab reduces risk of relapses in patients with neuromyelitis optica spectrum disorder.

The regulatory agency cited 2 concerns in the complete response letter: the risk of infections related to intravenous infusion ports and renal toxicity.

The genomic revolution has led to increasing opportunities to address complex neurodevelopmental conditions, taking a genetics-first approach.

The profound consequences of the results guide decisions about testing. Who should be tested? And, just as important, who should not?

In this podcast, Heidi Moawad, MD interviews Cesar Ochoa-Lubinoff, MD, MPH, FAAP, about recent encouraging clinical trial results in patients with Angelman syndrome.

Here’s a brief look at therapies for neurological disorders that the FDA has approved within the past 6 months.

EEG and brain MRI findings are normal-what do you suspect?

Are you up-to-date on recent guidelines for the management of agitation, anxiety, apathy, psychosis, and sleep disorders in patients with Huntington disease? Take this brief quiz to find out.

Some good news about Huntington disease: most of the behavioral symptoms can be managed with treatments developed for other conditions.

What is the most common risk factor for Guillain-Barré Syndrome? Plus 4 other quick questions to test your knowledge. 

A 32-year-old woman presents with common symptoms that made up a rare diagnosis never seen by the neurologist in a decades-long career.

Some studies have suggested that, over the long-term, CoQ10 may increase type 2 muscle fibers, which are sometimes atrophied in individuals with PPP.

A patient presented to the hospital with sudden-onset flaccid muscle weakness. Her family history was notable for sudden cardiac death of unknown etiology.

Strategies and take-home points on sleep paralysis and its counterpart, isolated sleep paralysis, a REM sleep-related parasomnia commonly associated with intense fear and anxiety.

Dengue infection predominantly causes arthritis, fever, headache, and rash; hemorrhagic and neurologic manifestations may also result. What was the prognosis for this patient?

A young child’s neurological exam was notable for symmetrical decreased muscle strength and absence of deep tendon reflexes in both lower extremities. Learn about the case here.

A 47-year-old man presented with a longstanding history of recurrent transient episodes of muscular weakness. What’s your diagnosis?

What are the considerations for addressing acute attacks? Are there specific strategies that have proved to be effective? These questions and more in this interview with a physician who has also “been there.”

About 30% of patients with periodic paralysis have unknown genetic mutation, making identification and treatment a challenge. Here: key points on genetics, testing, and subtypes of PPP.